This study is testing a drug called ABY-029 in people with high-grade glioma (a type of brain tumor). The main goals are to see if ABY-029 is safe and to figure out the best amount to use so surgeons can see the tumor more clearly during surgery. You would receive ABY-029 through an IV right before your planned tumor removal surgery. Researchers will then use a special imaging system during surgery to measure the drug in your tumor and surrounding tissue. The study is looking for 33 participants aged 18 or older who have a high-grade glioma suitable for surgery and are able to give informed consent. The study status is currently unclear.

Study design

This is an interventional study planning to enroll 33 participants. It compares two groups receiving different, very small amounts of ABY-029.

What's involved

You would receive ABY-029 via IV injection 1-3 hours before surgery. All research procedures, including image and measurement data collection and biopsy sampling, occur during surgery.

Compensation

Not stated in the trial record.

Follow-up

Researchers will monitor for adverse events related to ABY-029 for one month. They will also assess the false negative rate of ABY-029 fluorescence for up to three months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.